One of the challenges for most researchers is how to identify those limited RPL cases with genetic defects who are destined to miscarry, from other treatable ones. 4e6 In addition, screening for inherited or acquired thrombophilias (especially FVL and prothrombin gene mutations, such as prothrombin G20210A gene mutations, and protein C, protein S, and antithrombin deficiencies, as noted by Kazerooni et al, might be reasonably acceptable when patients have personal history of venous thromboembolism in a nonrecurrent risk factor setting, or if there is a first-degree relative with a known or suspected high-risk thrombophilia. However, any association between hereditary thrombophilias and RPL has not been supported by two prospective cohort studies. 2, 7 In addition, it is acknowledged that APS is the only thrombophilia known to have a direct influence on pregnancy loss, although much research has been devoted to better ascertain the role of thrombophilia in RPL. 8 PCOS, a common endocrinopathy characterized by oligoor anovulation, clinical or biochemical hyperandrogenemia, and polycystic ovaries on ultrasonography, affects 5e10% of women of reproductive age. 9, 10 The search for a specific endocrine abnormality or hematologic parameter as a predictor of pregnancy failure remains elusive. 11 Extensive and evidence-based study in this group of patients related to RPL and thrombophilia is supposed to be more efficient and valuable than sporadic case reports.
In their research, Kazerooni and colleagues studied this particular group of patients (with a combination of PCOS and RPL), and showed an elevated level of thrombophilic parameters in this population. 1 As predicted, this group of patients also had higher levels of testosterone and dehydroepiandrostrone sulfate, a higher fasting insulin level, and increased homocysteine levels. It is interesting to find a higher prevalence of FVL mutations in this specific group of patients compared to those PCOS patients without RPL. Therefore, the authors concluded that hyperinsulinemia, hyperandrogenemia, hypofibrinolysis, hyperhomocysteinemia, activated protein C ratio, and FVL mutations are associated with an increased ratio of RPL in patients with PCOS. This study supports the previously published concept that complicated alterations in endocrinologic, metabolic, and thrombophilic status are associated with RPL in patients with PCOS.
11e13 As for detectable genetic disorders, Kazerooni et al's study also supports the fact that FVL mutation is associated with RPL in women with PCOS.
However, Kazerooni and his colleagues failed to ultimately provide convincing information, because they did not provide any reliable and strict criteria to identify these patients with genetic disorders. Consequently, the heterogeneity of the study population and the absence of a medication history compromised the value of this article, although the underlying issue remains controversial.
In fact, extensive studies related to genetic mutations including FVL, the methylene tetrahydrofolate reductase gene, prothrombin, and the presence or absence of homozygosity in this specific group of patients have been conducted in different countries, with varying results and conclusions. 7, 12, 13 A combination of multiple inherited thrombophilia mutations from both parents rather than one specific defect of maternal origin was believed to be the possible reason for an adverse pregnancy outcome, similar to prenatal genetic consultation, 4e6 which contains many issues to be considered, including ethical, social, and medical problems, since it is hard to make a decision only based on these still uncertain data. To provide proper and cost-effective preconception genetic testing or even a preimplantation embryonic genetic diagnosis for infertile couples with an adverse pregnancy experience, a more detailed division of RPL into embryonic or post-embryonic stages, first or second trimesters, and an idiopathic or otherwise cause could more effectively aid in identifying the correct and sufficient combination of genetic defects for different categories of pregnancy loss.
In conclusion, the cause of RPL is multifactorial, and recent guidance on the investigation and management of women with RPL has been issued by the Royal College of Obstetricians and Gynecologist and the American College of Obstetricians and Gynecologists. 13 These recommendations reflect the lack of an evidence base in favor of thrombophilia testing and anticoagulant-based intervention. 13 Progressively more extensive testing is being performed, which leads, on many occasions, to results of questionable value. And although these vulnerable patients often look forward to receiving any intervention at all, unless they are fully informed of the evidence it may be still difficult for them to accept "no treatment," 14 although thromboprophylaxis with aspirin or heparin combined with metformin seems to be safe in pregnancy. The supportive delicate care and the need to intervene with medication to reduce guilt and anxiety may be ultimately provided. 8 
